Skip to main content
رجوع
COLL logo

Collegium Pharmaceutical, Inc.

جودة البيانات: 100%
ذروة بيع
COLL
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 33.25
▲ KWD 0.02 (0.06%)
القيمة السوقية: 1.06B
نطاق اليوم
KWD 33.20 KWD 33.76
نطاق 52 أسبوعًا
KWD 23.23 KWD 50.79
حجم التداول
634,834
متوسط 50 يوم / 200 يوم
KWD 43.32 / KWD 38.94
الإغلاق السابق
KWD 33.23

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E 16.8 0.3
P/B 3.5 3.0
ROE % 23.7 3.7
Net Margin % 8.1 3.8
Rev Growth 5Y % 29.6 10.0
D/E 3.1 0.2

السعر المستهدف للمحللين

Hold
KWD 58.00 +74.4%
Low: KWD 56.00 High: KWD 60.00
مكرر الربحية المستقبلي
4.10
ربحية السهم المستقبلية
KWD 8.11
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
809.53M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 9.39
KWD 8.49 – KWD 10.40
 767.90M 1
FY2029 KWD 8.88
KWD 8.03 – KWD 9.84
 741.80M 1
FY2028 KWD 7.24
KWD 6.55 – KWD 8.02
 662.95M 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-26 KWD 2.14 KWD 2.04 -4.7%
2025-11-06 KWD 1.86 KWD 2.25 +21.0%
2025-08-07 KWD 1.62 KWD 1.68 +3.7%
2025-05-08 KWD 1.43 KWD 1.49 +4.2%
2025-02-27 KWD 1.54 KWD 1.77 +14.9%
2024-11-07 KWD 1.59 KWD 1.61 +1.3%
2024-08-08 KWD 1.49 KWD 1.62 +8.7%
2024-05-09 KWD 1.47 KWD 1.45 -1.4%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 29.58% annually over 5 years — strong growth
ROE of 23.70% indicates high profitability
Debt/Equity of 3.12 — high leverage
Generating 327.58M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 5.96%
Cash machine — converts 521.05% of earnings into free cash flow

النمو

Revenue Growth (5Y)
29.58%
Revenue (1Y)23.62%
Earnings (1Y)-9.13%
FCF Growth (3Y)9.28%

الجودة

Return on Equity
23.70%
ROIC11.30%
Net Margin8.05%
Op. Margin23.97%

الأمان

Debt / Equity
3.12
Current Ratio1.57
Interest Coverage2.27

التقييم

P/E Ratio
16.79
Forward P/E4.10
P/B Ratio3.50
EV/EBITDA9.33
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 23.62% Revenue Growth (3Y) 17.36%
Earnings Growth (1Y) -9.13% Earnings Growth (3Y) 14.26%
Revenue Growth (5Y) 29.58% Earnings Growth (5Y) -3.17%
Profitability
Revenue (TTM) 780.57M Net Income (TTM) 62.87M
ROE 23.70% ROA 3.79%
Gross Margin 59.35% Operating Margin 23.97%
Net Margin 8.05% Free Cash Flow (TTM) 327.58M
ROIC 11.30% FCF Growth (3Y) 9.28%
Safety
Debt / Equity 3.12 Current Ratio 1.57
Interest Coverage 2.27
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 16.79 Forward P/E 4.10
P/B Ratio 3.50 P/S Ratio 1.35
PEG Ratio -3.12 Forward PEG N/A
EV/EBITDA 9.33 Fwd EV/EBITDA 4.72
Forward P/S 1.30 Fwd Earnings Yield 24.39%
FCF Yield 31.03%
Market Cap 1.06B Enterprise Value 1.75B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 780.57M 631.45M 566.77M 463.93M 276.87M
Net Income 62.87M 69.19M 48.16M -25.00M 71.52M
EPS (Diluted) 1.73 1.86 1.29 -0.74 1.86
Gross Profit 463.26M 377.34M 326.17M 209.49M 150.62M
Operating Income 187.08M 169.90M 166.96M 33.32M 17.63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.66B 1.66B 1.14B 1.17B 692.08M
Total Liabilities 1.36B 1.43B 947.88M 979.29M 489.15M
Shareholders' Equity 301.68M 228.84M 195.43M 194.84M 202.93M
Total Debt 940.56M 859.30M 674.28M 709.18M 258.75M
Cash & Equivalents 251.10M 70.57M 238.95M 173.69M 186.43M
Current Assets 691.41M 482.26M 537.60M 419.99M 315.54M
Current Liabilities 440.03M 509.51M 457.92M 433.73M 279.57M